MC# 17-36 - First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (enapotamab vedotin,HuMax®-AXL-ADC) in Patients with Solid Tumors

  • Agent(s): HuMax-AXl-ADC
  • Disease Type(s): Sarcoma, Melanoma, Lung-NSCLC
  • Phase(s): II
  • Drug Classification(s): Targeted Therapy, Immunotherapy, Monoclonal Antibody
  • Molecular Target(s): AXL

Mechanism of Action

GCT1021 (HuMax-AXL-ADC) is a human IgG1 antibody that is generated by conjugation of an Axl-specific antibody with a tubulin inhibitor (MMAE).  HuMax-AXL-ADC binds to the Ig1 domain of Axl and induces tumor cell killing by MMAE-mediated interference of cell division. Axl overexpression has been associated with resistance to kinase inhibitors.

Purpose

In this study, the sponsor and investigators want to learn:

  • The safety and tolerability of HuMax-AXl-ADC
  • How much HuMax-AXl-ADC is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from HuMax-AXl-ADC
  • How proteins that indicate the status of disease are affected with use of HuMax-AXl-ADC
Inclusion Criteria
  • For the expansion part: Patients with advanced and/or metastatic solid tumors who are not candidates for standard therapy , and for whom, in the opinion of the investigator, experimental therapy with enapotamab vedotin may be beneficial.
  • Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).
  • For the expansion patients must provide a fresh tumor biopsy at enrollment
  • Age ≥ 18 years.
  • Acceptable renal function
  • Acceptable liver function
  • Acceptable hematological status
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.
  • Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last infusion of enapotamab vedotin
  • Patients must provide a signed informed consent form before any trial relates activities are carried out.
Exclusion Criteria
  • Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first enapotamab vedotin administration.
  • Patient has a history of thromboembolic event(s) and is not willing to take thromboembolic prophylaxis.
  • Have clinically significant cardiac disease
  • Onset of unstable angina within six months of signing ICF
  • Acute myocardial infarction within six months of signing ICF
  • Known congestive heart failure (Grade III or IV as classified by the New York Heart Association); and/or a known decreased cardiac ejection fraction of <45% and/or baseline QT interval as corrected by Fridericia’s formula (QTcF) > 480 msec or uncontrolled atrial fibrillation.
  • Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg, despite optimal medical management
  • Ongoing or recent (within 1 year) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune related adverse events
  • Patients with a history of Grade 3 or higher immune related adverse events should be excluded (adverse events below Grade 3 should be discussed with the sponsor).
  • Patients with ongoing pneumonitis at screening or with a history of non-infectious pneumonitis that required steroids.
  • Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support 3 weeks prior to first enapotamab vedotin administration.
  • Have received a cumulative dose of corticosteroid ≥ 150 mg prednisone (or equivalent doses of corticosteroids) within two weeks before the first enapotamab vedotin administration.
  • History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.
  • Major surgery within four weeks before first enapotamab vedotin administration.
  • Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain metastases or stroke.
  • Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within five half-lives but maximum four weeks before first infusion. Accepted exceptions are bisphosphonates, denosumab and gonadotropin-releasing hormone agonist or antagonist.
  • Any prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload (Previous treatment with vinca alkaloids is allowed in line with inclusion criterion #1).
  • Radiotherapy within 14 days prior to first enapotamab vedotin administration.
  • Known past or current malignancy other than inclusion diagnosis, except for:
    • Cervical carcinoma of Stage 1B or less.
    • Non-invasive basal cell or squamous cell skin carcinoma.
    • Non-invasive, superficial bladder cancer.
    • Prostate cancer with a current PSA level < 0.1 ng/mL.
    • Breast cancer in BRCA1 or BRCA2 positive ovarian cancer patients.
    • Any curable cancer with a complete response (CR) of > 2 years duration.
  • Melanoma patients with an LDH ≥ 3 x ULN.
  • Ongoing significant, uncontrolled medical condition including:
  • Serious, non-healing wound, skin ulcer (of any grade), or bone fracture
  • Grade 2 or higher peripheral neuropathy.
  • Clinically significant active viral, bacterial or fungal infection
  • Known human immunodeficiency virus seropositivity.
  • Known positive serology for hepatitis B (unless due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy)
  • Known positive serology for hepatitis C (unless due to immunoglobulin therapy)
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the trial or evaluation of the trial result
  • History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of enapotamab vedotin
  • Body weight < 40 kg
  • Women who are pregnant or breast feeding.
  • Patients are not allowed to take part in any other interventional trial while participating in current trial.
  • Pulmonary hemorrhage or hemoptysis > 2.5 ml blood within 6 weeks unless cause has been addressed and is medically resolved.
  • History of acute pneumonitis.

Location

  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info: https://www.clinicaltrials.gov/ct2/show/NCT02988817?term=NCT02988817&rank=1

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 17-36